INTRODUCTION
============

Inflammation is a biological response of an organism to pathogens, including bacteria ([@R1], [@R2]). Immediately after the microbial invasion, the host immune system can recognize various microbial macromolecules, such as lipopolysaccharide (LPS) or DNA containing methylated CpG motifs through pattern recognition receptors including Toll-like receptors (TLRs) and various DNA sensors ([@R3], [@R4]). The activation of TLRs induces antibacterial responses through downstream signal transduction pathways, especially the activation of nuclear factor κB (NF-κB) and mitogen-activated protein kinase (MAPK), which results in the increased production of proinflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor--α (TNF-α) ([@R5]).

Host cells have multilevel mechanisms to negatively regulate inflammation and subsequently avoid harmful pathology associated with uncontrolled inflammatory responses ([@R6]). Previous studies including our research, have indicated that posttranslational modifications, such as ubiquitination and phosphorylation, play an important role in ensuring optimal immune responses ([@R7]--[@R11]). Recent studies suggest that epigenetic regulators, including KDMs (lysine-specific demethylases), are potent modulators of innate immunity ([@R12]). Aberrant histone modifications, such as trimethylation of histone H3 at lysine-27 (H3K27me3), are closely associated with inflammation ([@R13]). Generally, H3K27me3 modification at gene loci represses gene expression ([@R14], [@R15]). Demethylation of H3K27me3 is catalyzed by KDM6B (also called JMJD3) or KDM6A (also called UTX). KDM6B serves as a response gene to microbial products and inflammatory cytokines and regulates macrophage polarization ([@R16]--[@R18]). Previously, we demonstrated KDM6B-mediated ubiquitination in cellular reprogramming ([@R19]). The biological role of KDM6B in bacterial infection--induced inflammation and the molecular basis for interplay with other epigenetic modifications require further investigations.

As the most prevalent RNA epigenetic (epitranscriptomic) modification, *N*^6^-methyladenosine (m^6^A) modification is reversible and occurs cotranscriptionally ([@R20]--[@R25]). The m^6^A methylation is catalyzed by the methyltransferase complex including METTL3, METTL14, and WTAP, whereas its demethylation is mediated by FTO and ALKBH5 ([@R26]--[@R28]). The m^6^A modification is functionally interpreted by the m^6^A "reader" proteins, such as YTH-domain family 1-3 (YTHDF1-3) ([@R24], [@R29]). The m^6^A is important for the regulation of cell fate and many biological processes. A recent study has demonstrated that METTL3-mediated m^6^A methylation promotes dendritic cell activation ([@R30]). Viral infection can increase the levels of host m^6^A modification, which negatively regulates the type I interferon response ([@R31], [@R32]). Whether m^6^A also controls bacteria-induced inflammation response in host cells remains poorly understood.

In this study, we report that m^6^A exhibited a marked increase during bacterial infection, and was predominantly enriched in transcripts related to histone modification. Knockout (KO) of YTHDF2, an m^6^A reader, markedly enhanced demethylation of H3K27me3 on the promoters of proinflammatory cytokines (e.g., IL-6 and IL-12B), resulting in increased production of these cytokines during bacterial infection. In addition, we demonstrate that the mRNA of the H3K27me3 demethylase, *KDM6B*, showed m^6^A modification and could be degraded by YTHDF2. We defined H3K27me3 as an epigenetic barrier for m^6^A modification during inflammation. KDM6B facilitates the deposit of m^6^A via removal of the H3K27me3 barrier and recruitment of the m^6^A methyltransferase complex. Thus, our results not only reveal cross-talk between m^6^A and H3K27me3 during antibacterial response but also provide mechanistic insights into the potential use of m^6^A for preventing excessive inflammation.

RESULTS
=======

YTHDF2 deficiency enhances proinflammatory cytokine production during bacterial infection
-----------------------------------------------------------------------------------------

The role of m^6^A modification in bacterial infection was evaluated using an enzyme-linked immunosorbent assay (ELISA)--based m^6^A quantification assay. We quantified the m^6^A level in a heat-killed *Salmonella typhimurium* (HKST) infection model. The global m^6^A level of mRNA in THP-1 cells notably increased after HKST infection (fig. S1A). To define how bacteria enhance m^6^A modification of mRNA, we detected the expression level of m^6^A-modulated genes and found that the expression of WTAP increased in THP-1 cells during bacterial infection (fig. S1, B to D). In addition, the m^6^A modification of mRNAs in *WTAP* KO THP-1 cells did not change upon HKST treatment compared with untreated KO cells (fig. S1, E and F), suggesting that WTAP is responsible for the increased m^6^A modification upon bacterial infection. These findings drive us to explore the consequences of increased m^6^A modification caused by bacterial infection. The m^6^A-binding protein YTHDF2 has a critical role in the regulation of the decay of mRNAs containing m^6^A modification. Hence, we knocked out YTHDF2 in the THP-1 cells (a human monocyte cell line) via the CRISPR-Cas9 technology (fig. S2A) and analyzed the gene expression profiles of wild-type (WT) or *YTHDF2* KO THP-1 cells in response to HKST treatment ([Fig. 1A](#F1){ref-type="fig"}). Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses revealed that the up-regulated genes in the *YTHDF2* KO THP-1 cells were enriched in the cytokine production and the inflammatory signaling pathways ([Fig. 1B](#F1){ref-type="fig"}, fig. S2, B and C, and data file S1). Specifically, *YTHDF2* KO cells exhibited up-regulated expression levels of various proinflammatory cytokine genes, such as *IL6*, *IL12B*, *CCL22*, and *ICAM1* ([Fig. 1C](#F1){ref-type="fig"} and fig. S2D). These data suggested that *YTHDF2* KO promoted bacterial infection--induced inflammatory response.

![YTHDF2 deficiency enhances bacteria-induced inflammatory responses.\
(**A**) Heatmap of RNA-seq analysis showing differently expressed genes in WT versus *YTHDF2* KO THP-1 cells in response to HKST. (**B**) GO enrichment analysis of genes with substantially up-regulated transcription in *YTHDF2* KO THP-1 cells than that in WT THP-1 cells after treatment with HKST. (**C**) Scatterplot shows that *IL6*, *IL12B*, *CCL22*, and *ICAM1*are among the most notably up-regulated genes in *YTHDF2* KO THP-1 cells versus WT THP-1 cells. (**D**) WT or *YTHDF2* KO THP-1 cells were infected with HKST for indicated periods, and then *IL6* and *IL12B* mRNA expressions were analyzed. (**E**) WT or *YTHDF2* KO THP-1 cells were exposed to HKST, HKLM, or HKEB, and then the production of IL-6 was measured by ELISAs. (**F**) WT or *YTHDF2* KO THP-1 cells were stimulated with Pam3CSK4 (100 ng/ml), poly(I:C) (10 μg/ml), LPS (200 ng/ml), or CL097 (1 μg/ml) for 24 hours, and then the production of IL-6 was measured by ELISAs. (**G**) PBMCs that were transfected with *YTHDF2* siRNA or control siRNA for 48 hours were stimulated with HKST for indicated periods, and then *IL6* and *YTHDF2* mRNA expressions were analyzed. (**H**) THP-1^EV^ and THP-1^YTHDF2^ cells were stimulated with HKST for indicated periods, and then *IL6* and *IL12B* mRNA expressions were analyzed. (**I**) THP-1^EV^ and THP-1^YTHDF2^ cells were infected with HKST, HKLM, or HKEB for 24 hours, and the production of IL-6 was analyzed by ELISAs. (**J**) THP-1^EV^ and THP-1^YTHDF2^ cells were treated with LPS, poly(I:C), Pam3CSK4, or CL097 for 24 hours before the supernatants were collected. The production of IL-6 was analyzed by ELISAs. Data in (D) to (J) are presented as means ± SEM combined from three independent experiments with triplicate; ns, not significant, \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001 compared with control cells. STAT, signal transducers and activators of transcription.](aba0647-F1){#F1}

Quantitative real-time polymerase chain reaction (qRT-PCR) analysis revealed that the mRNA expression levels of *IL6* and *IL12B* in the *YTHDF2* KO THP-1 cells were markedly higher than those in the WT THP-1 cells upon stimulation with HKST ([Fig. 1D](#F1){ref-type="fig"}). Furthermore, we obtained similar results in the *YTHDF2* KO THP-1 cells after treatment with heat-killed *Listeria monocytogenes* (HKLM) or heat-killed *Escherichia coli O111:B4* (HKEB) (fig. S2E). ELISA analysis revealed that the *YTHDF2* KO THP-1 cells exhibited significant up-regulation of IL-6 production in response to HKST, HKLM, or HKEB treatment ([Fig. 1E](#F1){ref-type="fig"}). Furthermore, *YTHDF2* KO markedly enhanced the mRNA and protein expression levels of IL-6 in the THP-1 cells stimulated with LPS (a TLR4 ligand), Pam3CSK4 (a TLR2 ligand), or CL097 (a TLR7 ligand), but had little effect on polyinosinic:polycytidylic acid \[poly(I:C)\] (a TLR3 ligand) treatment ([Fig. 1F](#F1){ref-type="fig"} and fig. S2F).

Next, we investigated the effect of *YTHDF2* depletion on the inflammatory response in primary cells. We infected peripheral blood mononuclear cells (PBMCs) with HKST, LPS, or Pam3CSK4 and measured the expression levels of *IL6*. *YTHDF2* small interfering RNA (siRNA)--transfected PBMCs exhibited enhanced *IL6* mRNA expression levels under these stimuli when compared with the control cells ([Fig. 1G](#F1){ref-type="fig"} and fig. S2, G to I).

Furthermore, we generated a *YTHDF2*-overexpressing THP-1 cell line (THP^YTHDF2^) (fig. S2J) and observed that the ectopic expression of *YTHDF2* substantially reduced the IL-6 mRNA and protein expression levels under inflammatory stimulation ([Fig. 1, H to J](#F1){ref-type="fig"}, and fig. S2, J to L). These results indicate that YTHDF2 inhibits a subset of proinflammatory cytokines (e.g., IL-6) during bacterial infection in human cells.

Bacterial infection increases m^6^A level of the histone modification--related transcripts
------------------------------------------------------------------------------------------

To investigate the molecular mechanisms of YTHDF2 in regulating the bacterial infection--induced inflammatory response, we analyzed the activation of NF-κB and MAPK signaling pathways. As shown in fig. S3A, the phosphorylation and expression levels of IκB kinase (IKK), p65, p38, c-Jun N-terminal kinase (JNK), and extracellular signal--regulated kinase (ERK) were similar in the WT and *YTHDF2* KO cells in response to HKST. These findings indicated that YTHDF2 negatively regulates inflammation through a mechanism independent of NF-κB and MAPK signaling pathways.

Next, we examined whether YTHDF2 recognition of m^6^A RNA methylation directly contributes to the proinflammatory cytokine mRNA decay. We expressed the YTHDF2 truncation mutants (YTHDF2-N and YTHDF2-C) and m^6^A recognition site mutant (YTHDF2-WA) in the THP-1 cells ([Fig. 2A](#F2){ref-type="fig"} and fig. S3B). Overexpression of full-length YTHDF2 (YTHDF2-WT), but not truncated or mutated YTHDF2, reduced the mRNA and protein expression level of IL-6 ([Fig. 2B](#F2){ref-type="fig"} and fig. S3C). This result indicated that YTHDF2 negatively regulates the proinflammatory cytokine production via m^6^A recognition.

![m^6^A level of histone modification--related genes is increased during bacterial infection.\
(**A**) A structural diagram of WT YTHDF2 as well as schematic representation of truncation mutants and m^6^A recognition site mutations of YTHDF2. The numbers indicate amino acid positions. (**B**) The constructed YTHDF2 (WT) as well as YTHDF2 truncations (N and C termini) or site mutation (WA) THP-1 cell lines were exposed to HKST for 24 hours, and then the production of IL-6 was measured by ELISAs. (**C**) Sequence motif was identified within m^6^A peaks by HOMER analysis of WT and *YTHDF2* KO THP-1 cells with or without HKST treatment. (**D**) Pie charts depicting the proportion of m^6^A peak distribution in the 5′UTR, CDS, and 3′UTR regions across mRNA transcriptome. (**E**) Metagene profiles of m^6^A peak distribution across the 5′UTR, CDS, and 3′UTR in THP-1 cells with or without HKST treatment. (**F**) Scatterplot showing the m^6^A peaks in mRNA of HKST-treated and untreated THP-1 cells. The abundance of m^6^A peaks was calculated as enrichment fold (EF; immunoprecipitate/input) from the m^6^A-seq data. The m^6^A-containing transcripts with notably increased and decreased peaks are highlighted in red and blue, respectively. (**G**) GO analysis of the genes that contained hypermethylated m^6^A peaks in HKST-infected THP-1 cells versus the uninfected cells. MeRIP-seq, m^6^Aspecific methylated RNA immunoprecipitation combined with high-throughput sequencing. (**H**) GO analysis of a group of overlapped genes that bound to YTHDF2 based on the YTHDF2 RIP-seq data and contained hypermethylated m^6^A peaks after exposure to HKST in THP-1 cells.](aba0647-F2){#F2}

Using m^6^A sequencing (m^6^A-seq) analysis, we mapped the transcriptome-wide m^6^A methylation of WT and *YTHDF2*-deficient THP-1 cells with or without HKST stimulation. The consensus m^6^A core motifs were enriched within the m^6^A peaks in all samples ([Fig. 2C](#F2){ref-type="fig"}). There was a similarity in the total m^6^A distribution between the WT and *YTHDF2* KO cells with or without HKST treatment, which coincided with the typical m^6^A peak distribution features ([Fig. 2D](#F2){ref-type="fig"}). The m^6^A peaks were especially abundant around the start and stop codons ([Fig. 2E](#F2){ref-type="fig"}). HKST stimulation resulted in an elevated m^6^A peak across the entire gene bodies ([Fig. 2E](#F2){ref-type="fig"}). Meanwhile, the m^6^A-seq analysis revealed that the m^6^A peaks of 5155 transcripts increased in the THP-1 cells after treatment with HKST ([Fig. 2F](#F2){ref-type="fig"}). No m^6^A of *IL6* mRNA was found with or without HKST treatment. GO enrichment analysis indicated that these genes with increased m^6^A peaks were associated with the covalent chromatin and histone modifications ([Fig. 2G](#F2){ref-type="fig"}).

RNA immunoprecipitation sequencing (RIP-seq) was performed to explore the correlation among the YTHDF2-bound mRNAs (fig. S3D), particularly the mRNAs with elevated m^6^A modification after bacterial infection. Two biological replicates of RIP-seq exhibited a strong correlation (fig. S3E). We observed that 61.9% of the YTHDF2-bound mRNAs contain m^6^A peaks (fig. S3F). YTHDF2-bound mRNAs were specifically enriched in histone modification GO term (fig. S3G and data file S2). Intriguingly, YTHDF2 did not directly bind proinflammatory cytokine *IL6* mRNA (fig. S3H).

Consistently, combined analysis of YTHDF2-bound genes and m^6^A up-regulated genes revealed that these genes were enriched in histone modification ([Fig. 2H](#F2){ref-type="fig"}), suggesting that m^6^A has an important role in modulating bacterial infection--induced inflammation via regulating histone modification genes. These results suggest that the m^6^A modifications of histone modification--related gene mRNAs were markedly increased and are recognized by YTHDF2 in response to bacterial infection.

YTHDF2 inhibits H3K27me3 demethylation of *IL6* promoter during bacterial infection
-----------------------------------------------------------------------------------

In general, transcription start sites of active genes are marked with trimethylated H3K4 (H3K4me3) or acetylated H3K27 (H3K27ac), and inactive genes are marked with H3K27me3. Next, we determined whether *YTHDF2* depletion affects histone modification marks (H3K27me3, H3K4me3, and H3K27ac) in the THP-1 cells. The global levels of H3K27me3 in the *YTHDF2* KO THP-1 cells were markedly lower than those in the WT control, whereas those of H3K4me3 and H3K27ac were similar between the *YTHDF2* KO and WT cells in response to HKST ([Fig. 3A](#F3){ref-type="fig"}). Furthermore, chromatin immunoprecipitation sequencing (ChIP-seq) and ChIP qRT-PCR analyses revealed that the H3K27me3 modification of proinflammatory cytokine gene promoters (*IL6*, *IL12B*, *ICAM1*, and *CCL22*) in the YTHDF2 KO THP-1 cells was notably lower than that in the WT THP-1 cells ([Fig. 3, B and C](#F3){ref-type="fig"}). Contrastingly, there were no marked differences between YTHDF2 KO and WT THP-1 cells in the H3K4me3 modification levels in the proinflammatory cytokine promoters in response to HKST stimulation ([Fig. 3D](#F3){ref-type="fig"}). These data suggested that loss of YTHDF2 specifically enhances the expression of a subset of proinflammatory cytokines, such as IL-6 and IL-12B, during bacterial infection by facilitating H3K27me3 demethylation at their promoters.

![YTHDF2 inhibits H3K27me3 demethylation of *IL6* promoter.\
(**A**) WT and *YTHDF2* KO THP-1 cells were infected with HKST for indicated periods, and then the nuclear extracts were subjected to immunoblot analysis with the indicated antibodies. IB, immunoblot. (**B**) IGV browser tracks show the distribution of H3K27me3 ChIP-seq signals at indicated loci in WT and *YTHDF2* KO THP-1 cells stimulated with HKST. (**C** and **D**) ChIP-qPCR assay for H3K27me3 and H3K4me3 at the *IL6*, *IL12B*, *CCL22*, or *ICAM1* promoter region in WT and *YTHDF2* KO THP-1 cells infected with HKST or not. (**E**) WT and *KDM6B* KO THP-1 cells were exposed to HKST for indicated periods, and then the nuclear extracts were analyzed by immunoblotting with the indicated antibodies. (**F**) ChIP-qPCR assay for H3K27me3 and H3K4me3 at the *IL-6* promoter region in WT, *KDM6B* KO, *YTHDF2* KO, or *YTHDF2* and *KDM6B* double knockout (dKO) THP-1 cells in response to HKST. (**G**) WT, *YTHDF2* KO, *KDM6B* KO, or *YTHDF2* and *KDM6B* dKO THP-1 cells were infected with HKST for 24 hours, and supernatants were collected to analyze the production of IL-6 by ELISAs. Data in (A) and (E) are representative of three individual experiments with similar results. Data in (C), (D), (F), and (G) are presented as means ± SEM combined from three independent experiments with triplicate; \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001 compared with control cells (Student's *t* test). ns, not significant.](aba0647-F3){#F3}

KDM6A and KDM6B were identified as H3K27 demethylases, which catalyze the demethylation of H3K27me3. As *KDM6A* expression could barely be detected in THP-1 cells (fig. S4A), we generated the *KDM6B* KO THP-1 cells to evaluate the role of KDM6B in regulating inflammatory response (fig. S4, B and C). *KDM6B* deficiency had no effect on the activation of NF-κB and MAPK signaling pathways (fig. S4D). As expected, immunoblotting and ChIP-qPCR analyses revealed that *KDM6B* depletion enhanced the global H3K27me3 modification ([Fig. 3E](#F3){ref-type="fig"}) and H3K27me3 modification of *IL6* promoter (fig. S4E) with or without HKST stimulation. Consistently, the deficiency of *KDM6B* substantially decreased the mRNA and protein expression levels of IL-6 in response to HKST (fig. S4, F and G).

To further confirm the role of KDM6B in YTHDF2-mediated inflammatory response, we generated *YTHDF2* and *KDM6B* double-KO (dKO) THP-1 cells (fig. S4H). Intriguingly, *KDM6B* deficiency rescued *YTHDF2* deficiency--attenuated H3K27me3 modification of *IL6* promoter both under normal and HKST-stimulated conditions ([Fig. 3F](#F3){ref-type="fig"}). However, H3K4me3 modification of *IL6* promoter was not affected in *KDM6B* and *YTHDF2* dKO cells ([Fig. 3F](#F3){ref-type="fig"}). Accordingly, dKO of *KDM6B* and *YTHDF2* failed to promote the transcription and production of IL-6 when compared with KO of *YTHDF2* ([Fig. 3G](#F3){ref-type="fig"} and fig. S4I). These results suggest that KO of *KDM6B* can rescue the up-regulation of proinflammatory cytokine release in the *YTHDF2*-deficient THP-1 cells during bacterial infection.

YTHDF2 binds and decays the *KDM6B* transcripts via an m^6^A-dependent mechanism
--------------------------------------------------------------------------------

RIP-seq analysis revealed that YTHDF2 recognized m^6^A peaks in the *KDM6B* transcripts but not in the *KDM6A* transcripts after HKST stimulation ([Fig. 4A](#F4){ref-type="fig"} and fig. S5A). The RIP-qPCR analysis revealed that YTHDF2 binds to the human *KDM6B* mRNA under normal condition and that this association is markedly enhanced in response to HKST stimulation ([Fig. 4B](#F4){ref-type="fig"}). qRT-PCR and immunoblot analyses further confirmed that YTHDF2 deficiency substantially increased the mRNA and protein expression levels of KDM6B, respectively ([Fig. 4, C and D](#F4){ref-type="fig"}, and fig. S5B). Consistently, knockdown of YTHDF2 in PBMCs (fig. S5C) increased the transcription of KDM6B both before and after HKST treatment ([Fig. 4E](#F4){ref-type="fig"}). These findings suggested that YTHDF2 recognition of m^6^A-modified *KDM6B* mRNA inhibits KDM6B expression.

![YTHDF2 degrades *KDM6B* mRNA via an m^6^A-dependent manner.\
(**A**) IGV tracks displaying YTHDF2 RIP-seq (top) and RNA-seq (bottom) read distribution in *KDM6B* mRNA of WT and *YTHDF2* KO THP-1 cells with HKST infection. (**B**) RIP-qPCR detecting the binding of YTHDF2 to the transcripts of *KDM6B* in THP-1 cells stimulated with and without HKST. (**C**) The expression of *KDM6B* analyzed by RT-PCR increased in *YTHDF2* KO versus WT THP-1 cells after infection with HKST for indicated periods. (**D**) Immunoblot analysis of KDM6B in WT and *YTHDF2* KO THP-1 cells exposed to HKST for indicated periods. (**E**) PBMCs were transfected with *YTHDF2* or control siRNA for 48 hours and then treated with HKST, and *KDM6B* transcription was analyzed by real-time PCR. (**F**) Representative mRNA profile of *KDM6B* at indicated time points after actinomycin D (5 μg/ml) treatment in WT and *YTHDF2* KO THP-1 infected with HKST. (**G**) RIP-qPCR detecting the binding region of YTHDF2 to the mRNA of *KDM6B* in THP-1 cell lines that overexpressed Flag-tagged *YTHDF2* (WT) as well as *YTHDF2* truncations (N and C termini) or site mutation (WA) exposed to HKST. (**H**) THP-1^EV^, THP-1^YTHDF2-WT^, THP-1^YTHDF2-N^, THP-1^YTHDF2-C^ (left), and THP-1^YTHDF2-WA^ (right) cells were stimulated with HKST for indicated periods, and then *KDM6B* expression was analyzed by real-time PCR. Data in (D) are representative of three individual experiments with similar results. Data in (B), (C), and (E) to (H) are presented as means ± SEM combined from three independent experiments with triplicate, \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001 compared with control cells.](aba0647-F4){#F4}

To explore whether YTHDF2 regulates KDM6B expression through mRNA decay, we measured the *KDM6B* mRNA level in THP-1 cells after treatment with the transcription inhibitor actinomycin D. Compared with the WT THP-1 cells, the remaining *KDM6B* mRNA levels were markedly higher in the *YTHDF2*-deficient cells ([Fig. 4F](#F4){ref-type="fig"}). The RIP-qPCR analysis revealed that the C-terminal RNA binding domain (YTHDF2-C) is responsible for the binding of YTHDF2 to *KDM6B* mRNA as well as full-length YTHDF2 (YTHDF2-WT), whereas the P/Q/N-rich N terminus (YTHDF2-N) did not bind to the *KDM6B* mRNA ([Fig. 4G](#F4){ref-type="fig"}). Consistently, mutation of m^6^A recognition sites of YTHDF2 (YTHDF2-WA: W432A, W486A, and W491A) resulted in complete loss of m^6^A binding ([Fig. 4G](#F4){ref-type="fig"}). Furthermore, overexpression of YTHDF2 truncation mutants or m^6^A recognition site mutants alone could not degrade *KDM6B* mRNA ([Fig. 4H](#F4){ref-type="fig"}). These results indicated that the enhanced *KDM6B* mRNA expression was due to reduced mRNA decay caused by insufficient recognition of m^6^A modification in the *YTHDF2*-deficient cells.

Next, we tested whether the regulation of Il6 production by Ythdf2 is conserved in murine macrophages. Unlike what we have found in human cells, transfection of murine macrophages with murine *Ythdf2* siRNA has no effect on *Il6* expression (fig. S6A). Furthermore, we analyzed Ythdf2 cross-linking and immunoprecipitation sequencing (CLIP-seq) data obtained in murine cells and found that the binding mRNA of murine Ythdf2 is quite different from that in human cells (fig. S6B). Ythdf2 did not recognize m^6^A peaks in murine *Kdm6a/6b* mRNAs (fig. S6, C and D), supporting YTHDF2 specifically mediates the mRNA processing of *KDM6B* in human cells.

*KDM6B* mRNA is m^6^A modified and is more stable in *YTHDF2* KO cells
----------------------------------------------------------------------

Genome-wide mapping of m^6^A methylation revealed that *KDM6B* mRNA exhibited significant m^6^A peaks (at 2439, 2461, 2837, and 3065) in the coding sequence (CDS) region ([Fig. 5, A to C](#F5){ref-type="fig"}). These m^6^A methylations were increased when treated with HKST. Next, we cloned the 690--nucleotide (nt)--long WT or mutant CDS truncation sequence (from 2407 to 3096) into a Renilla luciferase (Rluc) reporter ([Fig. 5D](#F5){ref-type="fig"}). Consistent with the function of m^6^A modification in the regulation of *KDM6B* mRNA stability, the Rluc activity of mutant reporter was higher than that of the WT reporter under normal condition, even though both reporters were cloned under the same promoter ([Fig. 5E](#F5){ref-type="fig"}). The ectopic expression of *YTHDF2* substantially inhibited the Rluc activity of the WT reporter, and this inhibition was impaired by mutations in the m^6^A consensus sites ([Fig. 5E](#F5){ref-type="fig"}). Accordingly, the relative Rluc mRNA level of *KDM6B*-WT-luc (but not *KDM6B*-MUT) was largely decreased by YTHDF2 overexpression ([Fig. 5E](#F5){ref-type="fig"}). Consistently, the binding of YTHDF2 on Rluc was abrogated due to the mutations at the m^6^A sites ([Fig. 5F](#F5){ref-type="fig"}). KO of *YTHDF2* increased the Rluc activity and delayed mRNA degradation of WT reporter but not that of the mutant reporter ([Fig. 5G](#F5){ref-type="fig"}).

![Identification of specific m^6^A modification sites in *KDM6B* mRNA.\
(**A**) IGV browser tracks showing that m^6^A peaks were enriched in the CDS of the *KDM6B* transcript from the m^6^A-seq data. IP, immunoprecipitation. (**B**) m^6^A-qPCR analysis of *KDM6B* mRNA in WT THP-1 cells with or without HKST infection. (**C**) Schematic representation of the position of m^6^A motifs within the *KDM6B* transcript. (**D**) Schematic diagram of *KDM6B* WT (*KDM6B*-WT-luc) and *KDM6B* mutant (*KDM6B*-MUT-luc) reporters. The 690-nt DNA sequence of the WT *KDM6B* segment sequence was inserted to the dual-luciferase reporter plasmid to give rise to the *KDM6B*-WT-luc reporter. For the *KDM6B*-MUT-luc, A--C substitutions were made within the m^6^A consensus. (**E**) Relative dual-luciferase reporter activity and mRNA level of WT (*KDM6B*-WT-luc) or mutated (*KDM6B*-MUT-luc) reporters in HeLa cells with ectopically expressed YTHDF2. (**F**) RIP-qPCR detecting the binding of YTHDF2 to the transcripts of *KDM6B*-WT-luc or *KDM6B*-MUT-luc reporter in HeLa cells. (**G**) Relative dual-luciferase reporter activity and mRNA level of WT (*KDM6B*-WT) or mutated (*KDM6B*-MUT) reporters in WT or *YTHDF2* KO HeLa cells. (**H**) Schematic depiction of mutation of the m^6^A site in the KDM6B CDS region. (**I** and **J**) Full-length WT or mutant (MUT) *KDM6B* CDS regions were ectopically expressed in HeLa cells. After 24 hours, *KDM6B* mRNA levels were measured by RT-PCR (I), or cells were treated with actinomycin D (5 μg/ml) and total mRNA at indicated time points were collected to analyze the remaining *KDM6B* mRNA (J). (**K**) THP-1 cells stably expressing WT or mutant (MUT) *KDM6B* CDS fragment were infected with HKST for 6 hours, and then the binding of YTHDF2 was detected by RIP-qPCR. Data in (B), (E) to (G), and (I) to (K) are presented as means ± SEM combined from three individual experiments with triplicate. \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001 compared with control cells.](aba0647-F5){#F5}

Furthermore, we assayed the stability of *KDM6B* transcripts by cloning the WT and mutant CDS sequence into a murine stem cell virus (MSCV)--based retroviral vector, respectively ([Fig. 5H](#F5){ref-type="fig"}). The mutant *KDM6B* mRNA was more stable than the WT *KDM6B* mRNA, which suggested that the methylation of the four adenosines is crucial for regulating the *KDM6B* mRNA stability ([Fig. 5, I and J](#F5){ref-type="fig"}). Last, the binding of YTHDF2 on *KDM6B* mRNA was abrogated by the mutations of the m^6^A sites in THP-1 cells ([Fig. 5K](#F5){ref-type="fig"}). In summary, these data indicate that m^6^A modifications (at 2439, 2461, 2837, and 3065) in the *KDM6B* CDS are required for the binding of YTHDF2 to *KDM6B* mRNA and for the YTHDF2-mediated *KDM6B* mRNA decay.

KDM6B recruits m^6^A methyltransferase complex and facilitates m^6^A modifications cotranscriptionally
------------------------------------------------------------------------------------------------------

Previously, we have reported that H3K36me3 guides m^6^A modification cotranscriptionally ([@R25], [@R33]). To identify the role of H3K27me3 demethylation in the dynamic regulation of m^6^A modification, we compared the genome-wide distribution of H3K36me3 and H3K27me3 modifications to that of the m^6^A in the transcriptome of the THP-1 cells. We found that the position of H3K27me3 peaks was exclusive with that of m^6^A and H3K36me3 peaks in HKST-treated THP-1 cells ([Fig. 6A](#F6){ref-type="fig"} and fig. S7A). Distributions of m^6^A were mostly in the region of H3K27me3-negative chromatin ([Fig. 6B](#F6){ref-type="fig"}). KO of H3K27me3 demethylase KDM6B resulted in a decrease in total m^6^A modification of mRNAs after HKST treatment (fig. S7B). Further genome-wide m^6^A-seq analyses showed that m^6^A signal around the stop codon of *KDM6B* KO THP-1 cells was significantly down-regulated compared with WT control during bacterial infection ([Fig. 6C](#F6){ref-type="fig"} and fig. S7C). Transcripts (9703) whose m^6^A modifications were significantly decreased in *KDM6B* KO cells ([Fig. 6D](#F6){ref-type="fig"}) were mainly enriched in the regulation of chromatin modification (fig. S7D). Moreover, inhibition of H3K27me3 demethylases by GSK-J4 also led to a global reduction in m^6^A modification on mRNAs ([Fig. 6E](#F6){ref-type="fig"}). In addition, the mRNA expression of H3K27me3 demethylases KDM6B is positively related to the m^6^A methyltransferase complex genes (METTL3, METTL14, and WTAP) in normal tissues (fig. S7E). These results imply H3K27me3 as a barrier for m^6^A deposition and suggest that the loss of H3K27me3 facilitates m^6^A methylation.

![KDM6B facilitates m^6^A deposition by recruiting m^6^A methyltransferase complex.\
(**A**) Distance of H3K27me3 to the nearest m^6^A peaks in HKST-infected THP-1 cells. (**B**) Percentages of m^6^A peaks in different regions in THP-1 cells with or without HKST infection. The m^6^A peaks were normalized with exomePeak. (**C**) Metagene profiles of m^6^A distribution in WT or *KDM6B* KO THP-1 cells treated with HKST. (**D**) Scatterplot of m^6^A in *KDM6B* KO or WT THP-1 cells infected with HKST. (**E**) m^6^A levels on poly(A) RNA of HKST-stimulated THP-1 cells treated with or without GSK-J4. (**F**) (Top) Distribution of m^6^A peaks across the *KDM6B* mRNA transcript in THP-1 cells treated with or without HKST and (bottom) distribution of H3K27me3 peaks across the *KDM6B* mRNA transcript in WT and *YTHDF2* KO THP-1 cells treated with HKST. (**G** and **H**) m^6^A RIP-qPCR (G) and YTHDF2 RIP-qPCR (H) analyses of *KDM6B* mRNA in DMSO- or GSK-J4--treated THP-1 cells in response to HKST. (**I**) *KDM6B* mRNA expression in HKST-stimulated THP-1 cells or PBMCs with or without GSK-J4 treatment. (**J**) HKST-stimulated THP-1 cells were treated with DMSO or GSK-J4 for 24 hours, and then total mRNA were collected at 0, 2, or 4 hours after actinomycin D treatment to analyze the remaining *KDM6B* mRNA. (**K**) Coimmunoprecipitation of KDM6B and METTL3/14. WCL, whole cell lysate. (**L**) ChIP and ChIP-re-ChIP analysis of the association of KDM6B and METTL14 with the *KDM6B* genome DNA in HeLa cells transfected with Flag-tagged KDM6B or/and hemagglutinin (HA)--tagged METTL14. (**M**) Reduction in METTL14 at *KDM6B* gene body in HA-tagged METTL14-transfected HeLa cells with or without GSK-J4 treatment. Data in (K) are representative of three individual experiments with similar results. Data in (E), (G) to (J), (L), and (M) are presented as means ± SEM. \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001 compared with control.](aba0647-F6){#F6}

This interplay of H3K27me3 demethylation and m^6^A deposition was found in the individual representative genes, such as *KDM6B*, in HKST-stimulated THP-1 cells ([Fig. 6F](#F6){ref-type="fig"}). We further used GSK-J4 to inhibit H3K27me3 demethylation and investigated the casual regulation of H3K27me3 demethylation on m^6^A deposition at the *KDM6B* locus. GSK-J4 treatment inhibited m^6^A deposition ([Fig. 6G](#F6){ref-type="fig"}) and subsequently impaired YTHDF2 binding on *KDM6B* mRNA ([Fig. 6H](#F6){ref-type="fig"}). The mRNA expression levels are determined by the interplay of RNA production and degradation. Although GSK-J4 suppressed the transcription of KDM6B (fig. S7F), GSK-J4 treatment still increased the mRNA level of *KDM6B* in THP-1 cells and PBMCs ([Fig. 6I](#F6){ref-type="fig"}), owing to the inhibition of m^6^A and YTHDF2-mediated mRNA decay ([Fig. 6J](#F6){ref-type="fig"}). Consistently, we found that the H3K27me3 demethylation is required for the transcriptional activation of *IL6* during HSKT-induced inflammation in THP-1 cells and PBMCs through GSK-J4 treatment experiments (fig. S7G).

Mechanistically, we found that KDM6B interacted with the m^6^A methyltransferase complex components METTL3 and METTL14 ([Fig. 6K](#F6){ref-type="fig"} and fig. S7H). The binding seemed to be specific during transcription, as the interaction between KDM6B and METTL14 was also observed at the *KDM6B* gene locus using ChIP and re-ChIP assays ([Fig. 6L](#F6){ref-type="fig"}). Furthermore, inhibition of H3K27me3 demethylation by GSK-J4 showed that depletion of KDM6B demethylase activity impaired the binding of the METTL4 on the *KDM6B* gene locus ([Fig. 6M](#F6){ref-type="fig"}), suggesting that H3K27me3 demethylation is critical for the recruitment of the m^6^A methyltransferase complex cotranscriptionally.

DISCUSSION
==========

The m^6^A is the most prevalent mRNA modification in eukaryotic cells, but the interplay of m^6^A and histone modifications remains elusive. In this study, we revealed that m^6^A negatively regulated the inflammatory response through modulating H3K27me3, indicating the importance of m^6^A in maintaining immune homeostasis. Depleting m^6^A reader YTHDF2 expression limits the mRNA decay of *KDM6B* and promotes H3K27me3 demethylation, which is required for the activation of proinflammatory cytokine gene (e.g., *IL6*) transcription (fig. S7I, left). Meanwhile, H3K27me3 demethylation facilitates m^6^A deposition on histone modification genes (e.g., *KDM6B*), which enhances the mRNA decay to restrain inflammation (fig. S7I, right). The findings on the interplay of m^6^A RNA modification and histone modification also provide mechanistic insight for the regulation of proinflammatory cytokine gene expression.

Both m^6^A methylation and histone modification are reported to be essential for cell state transition. In most cases, bacteria elicit histone modifications and chromatin remodeling to inhibit the host innate immune response ([@R34]--[@R36]). Therefore, studying the regulatory role of m^6^A in histone modification during the bacterial infection would provide new insights into the mechanisms of pathogen altering host epigenome. Here, we found that various nascent transcripts gained m^6^A modification in the process of inflammation. Our YTHDF2 RIP-seq and m^6^A-seq data revealed that the gained m^6^A peaks induced by bacterial infection and bound by YTHDF2 are predominantly enriched in the histone modification transcripts (e.g., *KDM6B*). We noted that the KO of *YTHDF2* markedly reduced the H3K27me3 modification through decay of *KDM6B* mRNA in the THP-1 cells infected with bacteria, leading to markedly increased production of proinflammatory cytokines. Notably, although YTHDF2 mediated the degradation of the *KDM6B* transcript, the overall expression of KDM6B was increased due to its markedly increased transcription during the bacterial infection. Thus, our findings uncover a mechanism that reveals the role of m^6^A in modulating H3K27me3 modification in the host cells and provide the basis for explaining the up-regulated IL-6 production in the YTHDF2-deficient cells. The contribution of the m^6^A on other histone modification transcripts in the regulation of inflammation needs to be further determined.

The mechanism that underlies the dynamic deposition of m^6^A modification during transcription is largely unknown. Our previous work showed that H3K36me3 guides m^6^A methylation during the process of gene transcription, which suggested the importance of histone modification for the establishment of mRNA m^6^A methylation ([@R33]). Note that H3K36me3 and H3K27me3 occupy exclusive domains of the chromatin, and H3K27me3 rarely coexisted with H3K36me3 on the same histone H3 tail ([@R37]--[@R39]). We hypothesize H3K27me3 as a barrier for m^6^A modification. We found that m^6^A modifications are reduced globally when H3K27me3 demethylase is depleted or inhibited. Mechanistically, we first reveal the important role of the interaction between KDM6B and METTL14 in the control of m^6^A deposition. It is known that manipulation of the H3K36me3 methyltransferase SET domain containing 2 (SETD2) changes H3K36me3 and corresponding m^6^A modification in human and mouse transcriptomes. Moreover, the METTL14 could interact with H3K36me3 and the transcribing RNA polymerase II (Pol II) ([@R33]). A previously recognized model showed that Pol II recruits components of the histone modification complexes, such as KDM6B, which can directly interact with SETD2, to mediate methylation of H3K36me3 and H3K27me3 demethylation ([@R40]). Although it is still unknown whether KDM6B interacted with METTL14 or SETD2 when encountering RNA Pol II, our study suggested that METTL14 recognizes H3K36me3 through KDM6B-mediated recruitment and removal of H3K27me3 barrier.

There are diverse roles of YTHDF2 under different circumstances. YTHDF2 is responsible for transporting mRNAs from translation pools to P bodies ([@R41]). YTHDF2 mediates two degradation pathways of mRNAs with m^6^A modifications: (i) deadenylation via the YTHDF2-CCR4/NOT complex ([@R42]) and (ii) endoribonucleolytic cleavage by the YTHDF2--HRSP12--ribonuclease P/mitochondrial RNA--processing complex ([@R43], [@R44]). Another report showed that YTHDF2 promotes cap-independent translation initiation by increasing 5′ untranslated region (5′UTR) methylation in m^6^A modification ([@R45]). We believe that the RNA degradation machinery enables YTHDF2 to negatively regulate inflammatory response by degrading the m^6^A-modified transcripts selectively during bacterial infection. Although it has been reported that the C-terminal domain of YTHDF2 binds to mRNA with m^6^A methylation, the mechanism underlying the target specificity of YTHDF2 on the m^6^A mRNAs is still unclear. In murine cells, Ythdf2 target transcripts revealed enrichment of genes related to regulation of oxidative phosphorylation as well as regulation of histone acetylation ([@R46]). Notably, in human cells, we found that YTHDF2 mainly bound to histone modulator mRNAs, such as *KDM6B*, on sites largely overlapping with m^6^A peaks. We demonstrated that binding of YTHDF2 to KDM6B was only observed in human cells but not in murine cells. These results reveal that the YTHDF2-targeted mRNAs are species specific. Future studies are needed to clarify the details of this species-specific YTHDF2 function in human and mouse inflammation.

Bacterial infection induces the expression of hundreds of genes in the host cells, including proinflammatory cytokines, chemokines, antimicrobial proteins, and coagulation factors. Both *IL6* and *TNF* act as proinflammatory cytokine genes, which can be activated by NF-κB and MAPK signaling pathways. In our study, we observed that bacterial infection--induced proinflammatory cytokine genes in the YTHDF2-deficient cells fall into two categories: IL-6, whose production was enhanced, and TNF-α, whose production was unaffected upon depletion of YTHDF2 when compared to those in the WT control. We reasoned that different categories of the proinflammatory cytokine gene loci should have different histone modification patterns to meet their regulatory requirements. KDM6B-mediated H3K27me3 demethylation is crucial for *IL6* gene transcriptional activation ([@R47]). In this study, we showed that many proinflammatory cytokines, such as IL12B, are also increased in *YTHDF2* KO THP-1 cells upon bacterial infection. Because IL-6 plays a central role in the integrated immune defense network against infection, we chose IL-6 as a proof of concept. Moreover, we observed that, in contrast to the *IL6* locus, which was enriched with H3K27me3 in the HKST-untreated THP-1 cells, H3K27me3 modifications at the *TNF* locus were undetectable. This finding suggested that the activation of *TNF* transcription does not require removal of the H3K27me3 barrier after bacterial infection, which can elicit a rapid antibacterial response. As many proinflammatory cytokine promoters are enriched with H3K27me3, the inhibition of H3K27me3 demethylation mediated by YTHDF2 will decrease the efficiency of innate host defenses. Although our data highlight the importance of m^6^A and YTHDF2 in the negative regulation of antibacterial responses, further studies are needed on the safe manipulation of the innate immune response and inflammation by targeting m^6^A and YTHDF2 for the clinical treatment of infectious diseases.

MATERIALS AND METHODS
=====================

Antibodies, reagents, and plasmids
----------------------------------

Antibodies against YTHDF2 (catalog number 24744-1-AP), β-tubulin (catalog number 10094-1-AP), lamin A/C (catalog number 10298-1-AP), YTHDF1 (catalog number 17479-1-AP), METTL3 (catalog number 15073-1-AP), and β-actin (catalog number 60008-1-Ig) were purchased from Proteintech. Antibody against YTHDF3 (catalog number A8395) was purchased from ABclonal. Antibody against Flag (catalog number A8592) was purchased from Sigma-Aldrich. Antibodies against WTAP (catalog number sc-374280) were purchased from Santa Cruz. Antibodies against the following proteins were purchased from Cell Signaling Technology: KDM6B (catalog number 3457), p-IKKα/β (catalog number 2697), p-IκBα (catalog number 9246), IκBα (catalog number 4814), p-p38 (catalog number 9211), p38 (catalog number 9212), p-JNK (catalog number 9251), JNK (catalog number 9252), p-ERK (catalog number 9101), ERK (catalog number 9102), FTO (catalog number 14386), H3K27me3 (catalog number 9733), and H3K4me3 (catalog number 9751). The anti--*N*^6^-methyladenosine (m^6^A) antibody (catalog number 202303) was purchased from Synaptic Systems. Antibodies against METTL14 (catalog number ab98166), ALKBH5 (catalog number ab234528), and H3K27ac (catalog number ab4729) were purchased from Abcam. LPSs (100 ng/ml; catalog number L4391-1MG) were purchased from Sigma-Aldrich. Pam3CSK4 (100 ng/ml), poly(I:C) (10 μg/ml), CL097 (1 μg/ml), HKST (10^6^ cells/ml), HKEB (10^7^ cells/ml), and HKLM (5 × 10^7^ cells/ml) were purchased from InvivoGen. Plasmid pCMV-HA-KDM6B (catalog number 24167) was purchased from Addgene. All plasmids were verified by Sanger sequencing before further analysis.

Cell culture and transfection
-----------------------------

The THP-1 cells \[American Type Culture Collection (ATCC), catalog number TIB-202\] were cultured in RPMI 1640 (Corning) supplemented with 10% (v/v) fetal bovine serum (FBS), 4 nM [l]{.smallcaps}-glutamine, penicillin (100 U/ml), and streptomycin (100 U/ml) (RPMI 1640 complete medium). The human embryonic kidney (HEK) 293T cells (ATCC, catalog number CRL-3216) were cultured in Dulbecco's modified Eagle's medium (Corning) supplemented with 10% (v/v) FBS, 4 nM [l]{.smallcaps}-glutamine, penicillin (100 U/ml), and streptomycin (100 U/ml). The PBMCs were separated from the peripheral blood of healthy donors. The isolated PBMCs were washed with Dulbecco's phosphate-buffered saline (DPBS; Corning) and cultured in RPMI 1640 complete medium. All cells were cultured at 5% (v/v) CO~2~ at 37°C in a CO~2~ incubator. The transfection of HEK293T cells was performed using Lipofectamine 2000 (Invitrogen). The transfection of THP-1 cells was performed using Lipofectamine RNAiMAX (Invitrogen) following the manufacturer's instructions.

Generation of KO cells by CRISPR-Cas9
-------------------------------------

Guide RNA (gRNA), which was designed using an online gRNA design tool (by Zhang Feng laboratory, <http://crispr.mit.edu/>), was subcloned into the pLentiCRISPRv2 vector for expressing gRNA and Cas9. This vector was transfected into the HEK293T cells along with the following two lentiviral packing plasmids: VSVG and Δ8.9. Next, the culture supernatants were collected at 48 hours after transfection. The culture supernatant was concentrated by ultracentrifugation before use for infection. The infection-positive cells were selected and enriched on the basis of the resistance to puromycin (InvivoGen) or Zeocin (InvivoGen). Monoclonal cells were screened by a limiting dilution assay and confirmed by sequencing of PCR fragments. Immunoblotting analysis of cell lysates was performed with the corresponding antibody. The gRNA sequences used for generating the KO cells are listed in table S1.

Immunoblotting
--------------

The proteins in the cell lysates were resolved by SDS--polyacrylamide gel electrophoresis using an 8 to 12% (w/v) gel. The resolved proteins were transferred to a polyvinylidene difluoride membrane (Bio-Rad). The membrane was blocked with 5% (w/v) skim milk prepared in TBS-T buffer (50 mM tris-HCl, 150 mM NaCl, and 0.05% Tween 20). The membrane was washed thrice with TBS-T and incubated with an appropriate primary antibody diluted in TBS-T buffer with 5% (w/v) skim milk. The membrane was subsequently visualized after incubating with the secondary antibody \[a horseradish peroxidase--conjugated anti-mouse or anti-rabbit immunoglobulin G (IgG) antibody\] in the ChemiDoc XRS system (Bio-Rad).

Small interfering RNAs (siRNAs) and RNA interference
----------------------------------------------------

The control nontargeting and *YTHDF2*-specific siRNAs were designed and synthesized by Bioneer Corporation. The sequences of siRNAs are listed in table S1. The cells (5 × 10^5^ cells/ml) were transfected with siRNA (final concentration of 20 μM) using Lipofectamine RNAiMAX (Invitrogen) following the manufacturer's instructions. The cells were used for further experiments at 48 to 72 hours after transfection.

Quantitative real-time polymerase chain reaction
------------------------------------------------

Total RNA was extracted using the TRIzol reagent (Invitrogen). The complementary DNA (cDNA) was synthesized using the StarScript II First-strand cDNA Synthesis Mix (GenStar Biosolutions, China). The qRT-PCR analysis was performed on a QuantStudio 6 Flex System (Applied Biosystems) with the SYBR Green qPCR SuperMix (GenStar Biosolutions). The relative expression levels were determined by the comparative threshold cycle (*C*t) quantification method. β-Actin was used as an internal control. The primers for qRT-PCR are shown in table S1.

RNA-seq and data analysis
-------------------------

The whole-cell total RNA was isolated using TRIzol reagent (Invitrogen) and quantified using NanoDrop 2000. The cDNA library was constructed using Annoroad Gene Technology. The sequencing was performed on an Illumina HiSeq 2500 platform. The high-quality reads were mapped to the human reference genome (hg19) using HISAT2. DESeq, an R package, was applied for differential gene expression analysis. We filtered the differentially expressed genes based on the false discovery rate (FDR) of \<0.05.

Enzyme-linked immunosorbent assay
---------------------------------

The culture supernatants of the cells treated with the stimuli were collected at the indicated time points after stimulation. The protein expression levels of human TNF-α and IL-6 were assessed using the BD OptEIA ELISA Kits (BD Biosciences) following the manufacturer's instructions.

ChIP-seq and ChIP-qPCR
----------------------

The cells cultured with or without stimuli were cross-linked with 1% (v/v) formaldehyde for 10 min at room temperature and processed according to the ChIP protocol described in the SimpleChIP Enzymatic Chromatin IP Kit (catalog number 91820, Cell Signaling Technology). ChIP-seq libraries were sequenced on a HiSeq 2000 platform at Annoroad Gene Technology. The primers used for ChIP-qPCR are listed in table S1.

RIP-seq and RIP-qPCR
--------------------

The RIP assay was performed following a previously described procedure with minor modifications. Briefly, the cells were seeded in a 150-mm dish at a density of 1 × 10^6^ cells/ml. The cells were harvested in RIP buffer \[150 mM KCl, 25 mM tris (pH 7.4), 5 mM EDTA, 0.5 mM dithiothreitol, 0.2% CA630, ribonuclease inhibitor (100 U/ml), and 1X protease inhibitors\]. The cell lysates were incubated with 4 μg of anti-YTHDF2 antibody or a control IgG at 4°C overnight. Next, the cell lysates were incubated with 50 μl of protein A/G-agarose beads at 4°C for 2 hours. The beads were washed thrice and resuspended in 150 μl of RIP buffer with 0.1% SDS and 30 μg of proteinase K and incubated at 55°C for 30 min. The immunoprecipitated and input RNAs were isolated using the TRIzol reagent and subjected to RIP-qPCR or RNA-seq (RIP-seq) analysis.

RNA methylation quantification by ELISA
---------------------------------------

Total RNA was isolated using TRIzol reagent, and mRNA was purified using a PolyATtract mRNA Isolation Systems Kit (Promega, Z5310). Then, the m^6^A levels were quantified in a 100-ng aliquot of mRNA with an ELISA-based EpiQuik m^6^A RNA Methylation Quantification Kit (EpiGentek, \#P-9008) according to the manufacturer's instructions.

m^6^A-seq assay
---------------

Total RNA was isolated using TRIzol reagent. m^6^A immunoprecipitation and library preparation were performed following the published protocol. Briefly, mRNA was purified using the Dynabeads mRNA Purification Kit (Thermo Fisher). The purified mRNA was fragmented using an RNA fragmentation reagent (Invitrogen). The anti-m^6^A antibody (Synaptic Systems) was used for immunoprecipitation of m^6^A-modified mRNA. The mRNAs were washed and eluted with m^6^A sodium salt (Sigma-Aldrich, M2780). The input and immunoprecipitation samples were both used to construct the libraries. The libraries were sequenced on an Illumina HiSeq 2500 platform.

RNA decay assays
----------------

The cells were treated with actinomycin D (5 μg/ml; Sigma-Aldrich, catalog number A9415) or dimethyl sulfoxide (DMSO) for 2 or 6 hours, respectively. The total RNA was isolated at indicated time points for reverse transcription and qRT-PCR analysis. The mRNA decay rate was calculated by normalizing the gene expression in the actinomycin D--treated cells to that in the DMSO-treated cells.

Dual-luciferase reporter assay
------------------------------

The fragment of exon 11 from the human *KDM6B* CDS containing the predicted m^6^A modification sites was amplified via PCR and cloned into the psiCheck2 plasmid (Promega) to form the dual-luciferase reporter vector KDM6B-WT (WT KDM6B). To mutate the putative m^6^A sites of KDM6B, site-directed mutations were introduced to generate the KDM6B-mutated type (MUT KDM6B). The HEK293T cells were seeded in a 96-well plate (4 × 10^4^ per well) and transfected with the reporter vectors. At 24 hours after transfection, the cells were lysed with a lysis buffer (Promega), and luciferase activity was measured using the Dual-Luciferase Reporter Assay Kit (Promega) on a Synergy 2 microplate reader (BioTek). The results were calculated by normalization of firefly luciferase activity to Renilla luciferase activity.

Sequencing data analysis
------------------------

To process the ChIP-seq data, we used Trim galore (v.0.5.0) and fastqc (v.011.2) for trimming the adaptors and filtering the raw reads. The high-quality reads were mapped to the UCSC (University of California Santa Cruz) hg19 reference genome using bowtie2 (version 2.3.4.3). Next, MACS2 (version 2.1.1) was used for peak calling. The genome coverage files for visualization were generated using deepTools. Peak browsing and representative snapshots capturing were performed using the Integrative Genomics Viewer (IGV; IGV2.4.10, Broad Institute).

The RIP-seq reads were mapped to the human genome (hg19) using HISAT2 with default settings. Differential gene expression was calculated using an R package, DEGSeq. The RIP targets were defined as genes with reads per kilobase per million reads (RPKM) of ≥1 and immunoprecipitation/input log~2~(fold change) of ≥1.5. For m^6^A-seq data, filtered reads were aligned to the human (hg19) genome using HISAT2, and all nonunique mapped reads or PCR duplicates were removed. Next, exomePeak, an exome-based peak-calling R package, was used to detect a significantly enriched m^6^A modification site (FDR, \<0.05; fold enrichment, ≥1.5) with default parameters. The changes in the expression level of m^6^A-modified gene in the control and treatment groups were analyzed using exomePeak. The consensus motif was determined using HOMER. The GO and KEGG analyses were performed on the gene lists obtained from the methods described above using an R/Bioconductor package clusterProfiler (version 3.10.0).
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